ACCC refuses to approve pharma agreement in rare patent settlement request

Australia’s antitrust authority has voiced its concerns about a proposed patent dispute settlement and licensing agreement between Celgene and two drugmakers, warning that it could distort competition between generic manufacturers.

Get unlimited access to all Global Competition Review content